Led a €3.1M financing round in Connecta Therapeutics via the Innvierte Science Tech Clave Innohealth fund to advance its Fragile X syndrome drug program.
CONNECTA Therapeutics is a clinical-stage biotech company leveraging its small-molecule neuroplasticity modulation platform to address unmet medical needs in central nervous system (CNS) disorders, focusing on pediatric neurodevelopmental conditions
CONNECTA Therapeutics is a clinical-stage biotech company leveraging its small-molecule neuroplasticity modulation platform to address unmet medical needs in central nervous system (CNS) disorders, focusing on pediatric neurodevelopmental conditions.